Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice

Biochemical Pharmacology

Volumn 72, Issue 10, 2006, Pages 1237-1245

  Nakagawa, Hiroo ^a   Takiguchi, Takako ^a   Nakamura, Mariko ^a   Furuyama, Atsuko ^a   Koyanagi, Satoru ^a   Aramaki, Hironori ^b   Higuchi, Shun ^a   Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

Cancer therapy; Chronopharmacotherapy; Circadian rhythm; Imatinib; PDGF receptor; Tyrosine kinase

Indexed keywords

ABELSON KINASE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MICE, INBRED ICR; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PYRIMIDINES; SARCOMA 180;

EID: 33750201262     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.08.002     Document Type: Article

References (30)

1. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
2. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (2006) 561-566
3. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
4. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
5. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
6. McGary E.C., Weber K., Mills L., Doucet M., Lewis V., Lev D.C., et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8 (2002) 3584-3591
7. Uehara H., Kim S.J., Karashima T., Shepherd D.L., Fan D., Tsan R., et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95 (2003) 458-470
8. Kim R., Emi M., Arihiro K., Tanabe K., Uchida Y., and Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103 (2005) 1800-1809
9. Levi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 17 (2006) 611-621
10. Lemmer B. Chronopharmacology and controlled drug release. Expert Opin Drug Deliv 2 (2005) 667-681
11. Lis C.G., Grutsch J.F., Wood P., You M., Rich I., and Hrushesky W.J. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther 2 (2003) 103-104
12. Ohdo S. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety. Drug Saf 26 (2003) 999-1010
13. Hrushesky W.J. Tumor chronobiology. J Controlled Release 74 (2001) 27-30
14. Levi F. Chronopharmacology and chronotherapy of cancers. Pathol Biol 44 (1996) 631-644
15. Ohdo S., Koyanagi S., Suyama H., Higuchi S., and Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 7 (2001) 356-360
16. Koyanagi S., Okazawa S., Kuramoto Y., Ushijima K., Shimeno H., Soeda S., et al. Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol 20 (2006) 573-583
17. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91 (1999) 163-168
18. Koyanagi S., Nakagawa H., Kuramoto Y., Ohdo S., Soeda S., and Shimeno H. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies. J Pharmacol Exp Ther 304 (2003) 669-674
19. Koyanagi S., Kuramoto Y., Nakagawa H., Aramaki H., Ohdo S., Soeda S., et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63 (2003) 7277-7283
20. Asano M., Yukita A., Matsumoto T., Kondo S., and Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55 (1995) 5296-5301
21. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283-1316
22. Pietras K., Sjoblom T., Rubin K., Heldin C.H., and Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
23. Chen Q.P., and Giannobile W.V. Adenoviral gene transfer of PDGF downregulates gas gene product PDGFalphaR and prolongs ERK and Akt/PKB activation. Am J Physiol Cell Physiol 282 (2002) C538-C544
24. Murakami-Mori K., Mori S., Bonavida B., and Nakamura S. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells. J Immunol 162 (1999) 3672-3679
25. Murakami-Mori K., Mori S., and Nakamura S. p38MAP kinase is a negative regulator for ERK1/2-mediated growth of AIDS-associated Kaposi's sarcoma cells. Biochem Biophys Res Commun 264 (1999) 676-682
26. LaMontagne Jr. K.R., Moses M.A., Wiederschain D., Mahajan S., Holden J., Ghazizadeh H., et al. Inhibition of MAP kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 157 (2000) 1937-1945
27. Hotfilder M., Sondermann P., Senss A., van Valen F., Jurgens H., and Vormoor J. PI3K/AKT is involved in mediating survival signals that rescue Ewing tumor cells from fibroblast growth factor 2-induced cell death. Br J Cancer 92 (2005) 705-710
28. Ohdo S., Arata N., Furukubo T., Yukawa E., Higuchi S., Nakano S., et al. Chronopharmacology of granulocyte colony-stimulating factor in mice. J Pharmacol Exp Ther 285 (1998) 242-246
29. Koyanagi S., Ohdo S., Yukawa E., and Higuchi S. Chronopharmacological study of interferon-alpha in mice. J Pharmacol Exp Ther 283 (1997) 259-264
30. Takane H., Ohdo S., Yamada T., Yukawa E., and Higuchi S. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice. J Pharmacol Exp Ther 294 (2000) 746-752